Clinical Trial Update: Reducing Acute Kidney Injury Occurence by Administering Angiotensin II [Phase 3]

View source ↗

Summary

Phase 3 trial investigating angiotensin II to reduce acute kidney injury in cardiac surgery patients with vasoplegia and hyperreninemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Surgery-associated Vasoplegia
• Kidney Injury

Drugs mentioned

• Angiotensin II (angiotensin II)

Snippet

Sponsor: Universität Münster | Conditions: Cardiac Surgery, Vasoplegia | Phase 3 | Status: COMPLETED